Affibody reported results from the first 10 patients to undergo PET imaging with its gallium-68 (Ga-68) ABY-025 tracer for detecting breast cancer.
The company is developing Ga-68 ABY-025 PET as a test to identify human epidermal growth factor receptor 2 (HER2) protein in solid tumors. The status of HER2 in tumors can help determine treatment approaches for patients.
In the study, participants with a previously biopsy-confirmed HER2-low metastatic breast cancer underwent a HER2-PET with Ga-68 ABY-025 followed by a new tumor biopsy guided by the results from the PET images. According to the results, uptake of the radiotracers was observed in cancer lesions in all patients with HER2-low metastatic breast cancer.
In addition, clear HER2 signals were seen in lesions from two patients with tumor biopsies that were HER2-negative, the company noted.
